Skip to content

Clinical study on the Zu zhibao inhibits absorption of ethylalcohol

Clinical study on the Zu zhibao inhibits absorption of ethylalcohol

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104106
Enrollment
Unknown
Registered
2025-06-11
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol intake

Interventions

A Group:Participants were randomly divided into two groups. Group A subjects fasted for more than 8 hours, and blood samples were taken to measure alanine transaminase (ALT), aspartate transaminase (A
B Group:Participants were randomly divided into two groups. Group B subjects fasted for more than 8 hours, and blood samples were taken to measure alanine aminotransferase (ALT), aspartate aminotransf

Sponsors

Central Hospital of Fengxian District, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Subjects are between 18 and 45 years of age. (2) No alcohol consumption is allowed within 3 days prior to the experiment. (3) Participants in a clinical trial who have no significant systemic disease (including physical, mental, and social) and whose measures are within the normal measuring range or have no clinical significance in the investigator's judgment. (4) Subjects voluntarily participate in this clinical study and complete a written informed consent signature.

Exclusion criteria

Exclusion criteria: (1) There is (or has) a history of alcohol addiction. (2) He is known to be allergic to alcohol. (3) Pregnant or breastfeeding. (4) People with diabetes mellitus, hypertension.coronary heart disease, liver and kidney insufficiency, cancer, renal failure, cerebral hemorrhage, cerebral apoplexy, cardiorespiratory insufficiency, myocardial infarction, cardiac stent and artificial pacemaker. (5) Persons with mental illness and loss of ability to function autonomously.

Design outcomes

Primary

MeasureTime frame
Changes in breath alcohol level and blood alcohol content;

Secondary

MeasureTime frame
Alanine transaminase;aspartate transaminase;blood sugar;

Countries

China

Contacts

Public ContactZhang Shan

Endocrinology and Metabolism Department, Central Hospital of Fengxian District, Shanghai

Shanzhang_@163.com+86 185 0174 1665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026